SAN FRANCISCO, June 23, 2026 /PRNewswire/ -- Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit, which seeks to represent investors who purchased or acquired Embecta common stock ...
Embecta Corporation faces structural decline in its core pen-needle business due to oral GLP-1 adoption and customer losses.
Shares of Embecta (EMBC) have been trading at multi-year lows as investors fear the overhang of GLP-1 success, with Embecta posting flattish sales at best, yet being able to post strong margins. That ...
Hosted on MSN
Embecta outlines $1.71B–$1.93B revenue target for 2026 as GLP-1 partnerships gain traction
CEO Devdatt Kurdikar indicated that Embecta has transitioned from its standup phase to its seed growth phase, stating the company is “firmly in the seed growth phase” focused on staying competitive in ...
Earlier this year it appeared that Embecta, a diabetes care company that spun off from BD in 2022, was finally back on track after a rocky 2025. The Parsippany, NJ-based company’s fiscal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results